RNRadouane Niamane

Radouane Niamane

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Radouane Niamane has a total of 56 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Factors Determining the Switch of the First Biological Treatment in Spondyloarthritis: Data from the RBSMR Registry

    by Oumaima Idrissi Ouali, Imane El Mezouar, Nessrine Akasbi, Salma Mikou, Moncef Maiouak, Ihssane Hmamouchi, Redouane Abouqal, Ahmed Bezza, Fadoua Allali, Rachid Bahiri, et al.

    Introduction: Despite the substantial progress made in the therapeutic management of spondylarthritis (SpA) after the advent of biotherapy, some patients still undergo, for various reasons, therapeutic switches to an alternative biological agent. This study aimed to identify the factors leading to the switch from the initial biological treatment in patients with SpA, with a view toward tailoring the prescription to the patient's profile. Methods: Adult patients (aged >18 years) with spondylarthritis treated with biotherapy were enrolled in a cohort derived from a national historical-prospective multicenter registry between June 2017 and January 2019. The selection was based on the ASAS criteria, and patients were assessed every six months with a planned three-year follow-up. Baseline demographics and disease characteristics at the time of biologic therapy initiation were collected. Factors determining the switch to first bDMARDs were identified through univariate and multivariate logistic regression, reporting odds ratios (OR) with 95% confidence intervals (CI). Results: A total of 194 SpA patients were included. By the end of follow-up, 46 patients (23.71%) had switched to a second biologic agent (TNFα inhibitor or secukinumab). This switch was significantly associated with: advanced age (p = 0.030), higher Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) (p = 0.024), and the absence of specific comorbidities, including heart disease and stroke (p = 0.011 for both). Conclusion: The new bio-medications have considerably improved the prognosis of patients suffering from chronic inflammatory rheumatism, necessitating regular monitoring to detect events that could lead to a treatment switch. In our study, we identified factors associated with therapeutic switching, particularly advanced age, a history of corticosteroid therapy, and specific comorbidities. These findings highlight potential risk factors; however, further studies with larger cohorts and immunogenicity data are required before firm clinical recommendations can be made.

  • Open Access

    What are the characteristics of paradoxical effects in the Biotherapies Registry of the Moroccan Society of Rheumatology?

    by Laila Taoubane, Abdellah El Maghraoui, Redouane Niamane, Ihsane Hmamouchi, Fadoua Allali, Rachid Bahiri, Ouafae Mkinsi, Hasna Hassikou, Imad Ghozlani, Bezza Ahmed

    Introduction: The main objective of our study was to assess the prevalence of paradoxical reactions in patients with chronic inflammatory rheumatism treated with biologic drugs, while secondary objectives were to determine the type of paradoxical reactions and to investigate associated factors.Material and methods: We conducted a descriptive cohort study using 36-month frozen data from the RBSMR registry. This is a registry promoted by the Moroccan Society of Rheumatology, including patients treated for rheumatoid arthritis (RA) or spondyloarthritis treated with a biologic drug. The paradoxical reaction was defined by the appearance of a pathology that could be treated by bio­logical drugs. We investigated the prevalence of paradoxical reactions, and the factors associated with their occurrence. Statistical analysis was performed using JAMOVI software.Results: We analyzed 440 patients in the RBSMR. Paradoxical reactions were found in 19 pa- tients (4.6%). The mean time to onset of paradoxical manifestations was 30 weeks (1–144 weeks). Uveitis was the most frequent paradoxical reaction, found in 9 patients, followed by psoriasis in 7 patients, and then pyoderma gangrenosum, lichen, and granulomatous dermatitis in only 1 patient each. These paradoxical effects were found predominantly in men (57.9% of cases). Etanercept was the most prescribed biologic, in 52.6% of patients with paradoxical reactions, followed by adalimumab in 21.1%, golimumab in 15.8%, and secukinumab in 5.3%. Permanent discontinuation of biological treatment was recommended for all patients. In univariate analysis, the occurrence of a paradoxical effect was related to sex (p = 0.05) and to disease activity in patients with RA (p = 0.04).Conclusions: Our study suggests that there is a low prevalence of paradoxical effects in our population. However, these are reactions that need to be identified and investigated to improve the mana­gement of our patients with chronic inflammatory rheumatism.


  • Open Access

    Real-world evidence of biological treatments in rheumatoid arthritis and spondyloarthritis in Morocco: results of the RBSMR registry

    by Najlae El Ouardi, Ihsane Hmamouchi, Redouane Abouqal, Fadoua Allali, Rachid Bahiri, Imane El Bouchti, Imad Ghozlani, Hasna Hassikou, Linda Ichchou, Saadia Janani, et al.

    Regional variability in the effectiveness and safety of biologic therapies for rheumatoid arthritis (RA) and spondyloarthritis (SpA) underscores the need for comprehensive assessment. The aim of this study was to provide real-world evidence of the effectiveness and the safety of biologic for RA, SpA including psoriatic arthritis, in the daily clinical practice. RBSMR registry was a multicenter, cohort study conducted in 10 university departments of rheumatology. The study included RA and SpA patients receiving biotherapy, either as an initiation or ongoing treatment, and investigated for 3 years. The statistical analysis was performed using JAMOVI software (T student test, Mann–Whitney U test, Chi-squared test, Fisher’s exact test, Paired T test and Wilcoxon test). 223 RA and 194 SpA were eligible. After 3 years of follow-up, DAS28 CRP (3.6 ± 1.4 versus 5.8 ± 1.0 at baseline) and ASDAS CRP (1.8[1-2.4] versus 3.5[2.5–4.4] at baseline) significantly improved; 13.8% of RA patients achieved remission based on DAS28 CRP and 20.1% of SpA patients achieved remission based on ASDAS CRP. Overall, 163 and 126 adverse events were reported in RA and SpA patients respectively. Infections were the most frequently reported events with an incidence of 11.8 and 13.4/100 patients-year in RA and SpA respectively. Total incidence rate of tuberculosis was 0.80 patient/100 patients-year. The RBSMR registry provides real-world insights into the effectiveness of biologics in the practice of rheumatology for RA and SpA patients in Morocco. It underscores the critical need for continued vigilance in monitoring and addressing adverse events, with a particular focus on tuberculosis infection.


  • Discontinuation of biologic therapy in patients with rheumatoid arthritis and ankylosing spondylitis: analysis from multicenter cohort study

    by N. El Ouardi, A. El Maghraoui, H. J. Djossou, L. Taoubane, A. M. Ghassem, H. Toufik, A. Majjad, S. Sadni, A. Mounach, I. Hmamouchi, et al.

    Despite of the availability of several effective bDMARDs, a significant proportion of rheumatoid arthritis (RA) and ankylosing spondylitis (AS) patients discontinued bDMARDs. The aims of this study were to analyze causes of bDMARDs discontinuation in RA and AS included in the Moroccan registry RBSMR. A historical prospective multicenter cohort study based on the RBSMR database at 12 months of follow-up, which included 225 RA and 170 AS. Using T student, Mann–Whitney U, chi-squared or Fischer exact tests, baseline demographic and clinical features were compared between patients discontinuing bDMARDs and patients remaining on initiated bDMARDs or switching bDMARDs. Logistic regression models were used to identify factors associated with drugs discontinuation. 61 RA discontinued bDMARDs and 47 AS interrupted anti-TNF. The most common reasons for drugs discontinuation were adverse events (7.5%) in RA patients and social security reimbursement problems (16.8%) in AS. RA patients discontinuing bDMARDs were more frequently first-line biological drugs users, more frequently female and had more comorbidities and lower DAS28 CRP than RA patients remaining on initiated bDMARDs or switching bDMARDs (p < 0.001, p = 0.01, p < 0.001 and p < 0.001 respectively). Female sex and comorbidities were the significant predictors of bDMARDs discontinuation in RA patients. Higher baseline BASDAI had a protective role on anti-TNF interruption in AS patients. Adverse events and social security reimbursement problems were the main reasons for drugs discontinuation in RA and AS patients respectively. Female sex and comorbidities in RA patients, baseline BASDAI in AS patients impacted bDMARDs discontinuation in real-life settings.


  • Prevalence of latent tuberculosis before biotherapy initiation in rheumatoid arthritis and spondyloarthritis: data from the Moroccan biotherapy registry

    by Lamia Oulkadi, Samira Rostom, Ihsane Hmamouchi, Salma El Hassani Sbai, Imane El Binoune, Bouchra Amine, Redouane Abouqal, Fadoua Allali, Lahsen Achemlal, Imane El Bouchti, et al.

    Before the initiation of biotherapy in the treatment of rheumatic diseases, it is highly recommended for the patients to be screened for latent tuberculosis infection (LTBI). The objective of this study is to identify the prevalence of LTBI among patients with rheumatoid arthritis (RA) and spondyloarthritis (SpA) before the initiation of biologic therapy in the Moroccan biotherapy registry (RBSMR). A cross sectional study was conducted using the baseline data of the Moroccan biotherapy registry. Tuberculin skin test or IGRA test or both tests were done before starting anti-TNF treatment for screening LTBI. The comparisons between positive and negative LTBI patients according to rheumatic disease were examined using categorical comparisons. 259 patients were included in this study.94 patients had RA and 165 had SpA. The mean age of the RA patients was 50.49 ± 11.82 years with a majority of females (84%). The mean age for the SpA patients was 36 ± 13.7 years with a majority of males (67.3%). The prevalence of LTBI in the RBSMR was 21.6%. This prevalence was at 24.8% in SpA patients, while it was at 15.9% for RA patients. After the comparison between positive and negative LTBI patients according to rheumatic disease, no demographic, clinical, or therapeutic characteristics were statistically associated with LTBI. This study found that in an endemic TB country like Morocco, a high prevalence of patients with SpA and RA had LTBI, and that RA patients had a lower prevalence than SpA patients.


  • Open Access

    AB0246 COMORBIDITIES APPEARING UNDER BIOLOGIC THERAPY: PREVALENCE AND ASSOCIATED FACTORS

    by T. El Joumani, T. Latifa, I. Hmamouchi, S. Ahid, R. Abouqal, L. Achemlal, I. El Bouchti, A. El Maghraoui, I. Ghozlani, H. Hassikou, et al.

    Objectives: The aims of our study are to determine the new comorbidities appearing under biologic therapy, their prevalence, and the factors implicated in their appearance. Methods: It’s a multicentric historical-prospective cohort including 10 rheumatology departments of Moroccan University Hospitals. The data were collected from the national register of patients under biologic therapy supervised by the Moroccan Society of Rheumatology. An electronic follow-up questionnaire is completed every 6 months by the investigator. Results: The study included 418 patients: 224 with Rheumatoid Arthritis (RA) who represented 53.6% and 194 with spondyloarthropathy (SP) who represented 46.4%. The prevalence rate of comorbidities appearing after one year of treatment with biologic therapy was 15.7% in RA and 8.4% in SP. The rate of cardiovascular diseases was 12.9% (arterial hypertension, myocardial infarction and/or ischemic stroke), 6.4% was the same value of hypercholesterolemia and depression, diabetes 3.3%, ulcer 3.2%, and osteoporosis 9.7%. The sedentary rate was 54.8% and smoking was about 3.3%. No patient had developed hypertriglyceridemia or chronic obstructive pulmonary disease. In the group of patients with RA, the average age of the patients who had developed a new comorbidity was 51,8 ± 11,3 years, women represented 87.5%, the average of Body Mass Index (BMI) was 27,6 ± 5,9 and the average duration of the disease was 14,1 ± 9,2 years. The disease activity score (DAS28) had an average of 3,15 ± 1,47. 59.6% of patients used Rituximab, 23.8% Tociluzimab, 8.1% Etanercept, 5.8% Adalimumab, 0.18% Infliximab, and 0.9% Golimumab. In the group of patients with SP, the average age of the patients who had developed a new comobidity was 40,2 ± 13,7 years, men represented 63.4%, and the average of BMI was 24,3 ± 4,94. The activity of the desease, had an average Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of 2,62 ± 1,79 and ankylosing Spondylitis Disease Activity Score (ASDAS) of 1,93 ± 1,09. Regarding the type of biologic therapy, 33.2% of patients used Etanercept, 30.1% Adalimumab, 24.9% Infliximab, 9.8% Golimumab, 1.6% Secukinumab, and 0.5% Tociluzimab. Conclusion: Our study showed a high prevalence of cardiovascular disease in patients under biologic therapy. This can be explained by the sedentary lifestyle secondary to rheumatic disease. Disclosure of Interests: None declared

  • Open Access

    AB0485 DOES THE REASON OF DISCONTINUATION OF THE FIRST TNF INHIBITOR INFLUENCE THE RESPONSE TO THE SECOND TNF INHIBITOR IN SPONDYLOARTHRITIS? PILOT STUDY FROM THE MOROCCAN RBSMR REGISTRY

    by T. Fatima Zahrae, T. Latifa, H. Rkain, I. Hmamouchi, L. Achemlal, I. El Bouchti, A. Elmaghraoui, I. Ghozlani, H. Hassikou, T. Harzy, et al.

    Background: In rheumatoid arthritis, studies have shown that the response to a second TNF inhibitor is better if the first TNF inhibitor was stopped for a secondary failure or adverse event compared to a primary failure [1,2]. However, few studies have provided evidence regarding the response to a second TNF inhibitor based on the reason for discontinuation of the first TNF inhibitor in patients with a diagnostic of spondyloarthritis (SpA). Objectives: To evaluate the efficacy of the 2nd TNF inhibitor in real life from a cohort of patients with SpA from the Moroccan registry of biological therapies in rheumatic diseases (RBSMR Registry), according to the reason for discontinuation of the 1st TNF inhibitor. Methods: We have included from the RBSMR Registry any patient with a diagnosis of SpA starting a 2nd TNF inhibitor on inclusion in the registry or during the 1st year of follow-up. A descriptive study was conducted by measuring the therapeutic maintenance of the 2nd TNF inhibitor as well as the disease activity in different groups of patients according to the reason for stopping the first TNF inhibitor: stopping for ineffectiveness, side effect or non-availability of the drug. Results: Of the total 194 patients with SpA included in the RBSMR registry, 40 patients were on their 2nd TNF inhibitor at one year follow-up. The mean age of the patients was 43.6 ± 15.1 with a male predominance (57.5%) and a mean of disease duration of 13.75±6.95 years. At 1 year, treatment was maintained in 72.5% of all patients: 100% after ineffectiveness, 82% after discontinuation for side effects and 52.9% for unavailability of the first TNF inhibitor. Moderate disease activity as defined by an Ankylosing Spondylitis Disease Activity Score using ASDAS-CRP Conclusion: This pilot study gives us a small insight into the fate and efficacy of the 2nd TNF inhibitor based on the reason for discontinuation of the first. The follow-up data at 2 and 3 years will allow us to include more patients and thus be able to do a real statistical study with a comparison between the different groups. References: [1]Remy A, Avouac J, Gossec L, Combe B. Clinical relevance of switching to a second tumour necrosis factor-α inhibitor after discontinuation of a first tumour necrosis factor-α inhibitor in rheumatoid arthritis: a systematic literature review and meta-analysis. Clin Exp Rheumatol. 2011;29:96–103. [2]Chatzidionysiou K, Askling J, Eriksson J, Kristensen LE, van Vollenhoven R, ARTIS group. Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register. Ann Rheum Dis. 2015;74:890–6. Disclosure of Interests: None declared.

  • One-year direct costs of biological therapy in rheumatoid arthritis and its predictive factors: data from the Moroccan RBSMR registry

    by Safaa Fellous, Hanan Rkain, Samir Ahid, Redouane Abouqal, Latifa Tahiri, Ihsane Hmamouchi, Lahsen Achemlal, Imane El Bouchti, Abdellah El Maghraoui, Imad Ghozlani, et al.

    The aim of the study was to estimate the annual direct costs of biological therapies in rheumatoid arthritis (RA), and to establish possible factors associated with those costs. The main data source was the Moroccan registry of biological therapies in rheumatic diseases (RBSMR Registry). We included patients with available 1-year data. Variables related to socio-economic status, disease and biological therapy were collected. Direct costs included prices of biologics, costs of infusions, and subcutaneous injections. Differences in costs across groups were tested by Mann–Whitney and Kruskal–Wallis tests. Correlations analysis was performed in search of factors associated with high costs. We included 197 rheumatoid arthritis patients. The mean age was 52.3 ± 11 years, with female predominance 86.8%. Receiving one of the following therapies: rituximab (n = 132), tocilizumab (n = 37), or TNF-blockers (n = 28). Median one-year direct costs per patient were €1665 [€1472–€9879]. The total annual direct costs were € 978,494. Rituximab, constituted 25.7% of the total annual budget. TNF-blockers and tocilizumab represented 27.3% and 47% of this overall budget, respectively. Although the costs were not significantly different in terms of gender or level of study, the insurance type significantly affected the cost estimation. A positive correlation was found between the annual direct cost and body mass index (r = 0.15, p = 0.04). In Morocco, a developing country, the annual direct costs of biological therapy are high. Our results may contribute to the development of strategies for better governance of these costs.


  • L'atteinte du pied au cours du rhumatisme psoriasique. À propos de 26 cas

    by A. Bezza, R. Niamane, B. Amine, A. El Maghraoui, R. Bensabbah, N. Hajjaj-Hassouni